Workflow
丸美生物(603983):二季度收入同比增长34%,投放加大为新品增长蓄力

Investment Rating - The investment rating for the company is "Outperform the Market" [6][4][17] Core Views - The company achieved a revenue of 1.769 billion in the first half of 2025, representing a year-on-year growth of 30.83%. The net profit attributable to the parent company was 186 million, up 5.21% year-on-year. However, the net profit for Q2 was 51 million, down 22.7% year-on-year due to increased promotional spending and new product launches [1][9][4] - The main brand, Marubi, and the second brand, Lianhuo, are working synergistically to drive revenue growth, with Marubi's revenue reaching 1.25 billion, a 34.36% increase year-on-year, accounting for 70.66% of total revenue [2][9] - The online channel revenue for the first half of 2025 was 1.571 billion, up 37.85% year-on-year, representing 88.87% of total revenue, while offline channel revenue decreased by 7.07% to 197 million [10][2] Financial Performance - The gross margin for Q2 2025 was 73.28%, down 1.47 percentage points year-on-year, while the net margin was 5.51%, down 4.10 percentage points year-on-year, primarily due to changes in product mix and participation in promotional activities [3][11] - The company’s operating cash flow for Q2 2025 was 143 million, a significant increase of 109.1% year-on-year, largely due to a low base effect from increased spending in the previous year [15][3] Future Outlook - The company is expected to continue its strategy of deepening its focus on major products and enhancing product innovation, which is anticipated to support healthy revenue growth in the future. However, increased spending on marketing and promotions is likely to exert pressure on profits in the short term [4][17] - The net profit forecasts for 2025-2027 have been adjusted to 447 million, 547 million, and 665 million respectively, with corresponding P/E ratios of 38, 31, and 25 times [4][5][17]